uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Allergen-loaded strontium-doped hydroxyapatite spheres improve allergen-specific immunotherapy in mice
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich.
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences, Applied Materials Sciences. (Materials in Medcine)ORCID iD: 0000-0002-7356-3002
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich.
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich.
Show others and affiliations
2017 (English)In: Allergy. European Journal of Allergy and Clinical Immunology, ISSN 0105-4538, E-ISSN 1398-9995, Vol. 72, no 4, p. 570-578Article in journal (Refereed) Published
Abstract [en]

Background

Immunomodulatory interventions play a key role in the treatment of infections and cancer as well as allergic diseases. Adjuvants such as micro- and nanoparticles are often added to immunomodulatory therapies to enhance the triggered immune response. Here, we report the immunological assessment of novel and economically manufactured microparticle adjuvants, namely strontium-doped hydroxyapatite porous spheres (SHAS), which we suggest for the use as adjuvant and carrier in allergen-specific immunotherapy (ASIT).

Methods and Results

Scanning electron microscopy revealed that the synthesis procedure developed for the production of SHAS results in a highly homogeneous population of spheres. SHAS bound and released proteins such as ovalbumin (OVA) or the major cat allergen Fel d 1. SHAS-OVA were taken up by human monocyte-derived dendritic cells (mdDCs) and murine DCs and did not have any necrotic or apoptotic effects even at high densities. In a murine model of ASIT for allergic asthmatic inflammation we found that OVA released from subcutaneously injected SHAS-OVA led to a sustained stimulation of both CD4+ and CD8+ T-cells. ASIT with SHAS-OVA as compared to soluble OVA resulted in similar humoral responses but in a higher efficacy as assessed by symptom scoring.

Conclusion

We conclude that SHAS may constitute a suitable carrier and adjuvant for ASIT with great potential due to its unique protein-binding properties.

Place, publisher, year, edition, pages
2017. Vol. 72, no 4, p. 570-578
National Category
Medical Materials
Identifiers
URN: urn:nbn:se:uu:diva-310479DOI: 10.1111/all.13041ISI: 000397489400007PubMedID: 27590538OAI: oai:DiVA.org:uu-310479DiVA: diva2:1057065
Funder
Swedish Research Council, 2013-5419
Available from: 2016-12-16 Created: 2016-12-16 Last updated: 2017-05-15Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Xia, WeiEngqvist, Håkan

Search in DiVA

By author/editor
Xia, WeiEngqvist, Håkan
By organisation
Applied Materials Sciences
In the same journal
Allergy. European Journal of Allergy and Clinical Immunology
Medical Materials

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 523 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf